❯ An unreleased life sciences model, gpt-rosalind-discovery, appears on OpenAI’s pricing page at the same price as the existing one

A new line on the pricing pageOpenAI’s API pricing page has added gpt-rosalind-discovery under “Life sciences models,” next to the existing gpt-rosalind-research, TestingCatalog reported on October 10. The two are priced the same: $5 per million input tokens and $25 per million output tokens. OpenAI has published no announcement, help article or system card for it.

Sold only to vetted organizationsGPT-Rosalind is the life sciences model OpenAI introduced in April for biology, drug discovery and translational medicine, with early partners including Amgen, Moderna, the Allen Institute and Thermo Fisher. On September 11 it left research preview and opened to eligible organizations worldwide, though they must be approved through a trusted-access program. Its system card says the model is trained not to refuse sophisticated biology questions, so gated access is the main safeguard.

The name points to drug discovery; the purpose is unconfirmedThe name suggests the new model may target drug discovery, such as target identification or molecular design, but TestingCatalog said this is a guess. OpenAI has not said whether it is a separately trained model or a differently tuned version of the existing one. OpenAI’s help center says the current model is most useful for early discovery and hypothesis generation, such as literature synthesis and omics interpretation; what the new one adds will have to wait for an official description and testing.

▮ SIGNALGeneral-purpose model companies are starting to split out industry-specific models and to control risk through gated access instead of the model’s own refusals.